1. Where the TARA story stands going into ASCO GU 2026

TARA-002 is Protara’s lead asset: an investigational cell-based immunopotentiator derived from Streptococcus pyogenes, conceptually similar to the older OK-432 product that has long clinical experience in Japan. Protara is repurposing and industrialising this biology for two main indications: non-muscle invasive bladder cancer (NMIBC) and pediatric lymphatic malformations (LMs).

The NMIBC programme, ADVANCED-2, is a Phase 2 open-label trial that includes two key cohorts:

• BCG-unresponsive CIS ± Ta/T1 — the group that will be in the spotlight at the ASCO GU 2026 poster on February 27.
• BCG-naïve CIS ± Ta/T1 — where Protara already showed promising complete response rates at SUO 2025, with data out to 12 months.

On January 22, 2026, Protara announced that updated interim data from the BCG-unresponsive cohort of ADVANCED-2 will be presented at the ASCO Genitourinary Cancers Symposium in San Francisco, specifically in a Friday poster session on February 27, 2026. The company reiterated that it is on track to report interim results from about 25 six-month evaluable BCG-unresponsive patients in Q1 2026.

The market tends to focus heavily on larger bladder cancer players, yet this is the first real “moment of truth” for an intravesical immunopotentiator that already has encouraging BCG-naïve data and deep regulatory support in a separate pediatric rare disease. That is exactly the kind of catalyst which often flies under the radar until very late.

In parallel, Protara is running STARBORN-1, a Phase 2 trial of TARA-002 in pediatric LMs. In late 2025 the company reported meaningful radiographic and clinical responses in children with macrocystic and mixed LMs, with a safety profile broadly consistent with historical OK-432 experience.

The LM story became much more serious on January 5, 2026, when the FDA granted TARA-002 both Breakthrough Therapy and Fast Track designations for pediatric LMs, on top of the existing Rare Pediatric Disease designation. TARA-002 was also selected into the FDA’s Chemistry, Manufacturing, and Controls CDRP programme, a pilot designed to help therapies with compressed development timelines scale manufacturing in sync with clinical progress.

2. What we already know from ADVANCED-2: BCG-naïve data and the “setup” for BCG-unresponsive

Before ASCO GU focuses attention on the BCG-unresponsive cohort, it is worth recapping what has already been seen in BCG-naïve patients. In a December 2025 update presented at the 26th Annual Meeting of the Society of Urologic Oncology (SUO) and detailed in a company press release, TARA-002 demonstrated:

• Any time complete response (CR) rate: ~72% in the evaluable BCG-naïve CIS ± Ta/T1 population.
• 6-month CR rate: roughly 69% among patients who had reached that timepoint.
• 12-month CR rate: around 50%, with ongoing follow-up.
• Safety: no Grade 3 or higher treatment-related adverse events in the data cut disclosed, with most events being low-grade local or systemic reactions.

Those numbers are broadly in line with earlier interim readouts Protara had already shared in 2024 and early 2025 for the BCG-naïve cohort, which pointed to durable responses and a favourable tolerability profile for intravesical TARA-002.

The importance of these data goes beyond the naïve segment:

• They help establish a dose, schedule and administration protocol that can be ported into the unresponsive setting and into future registrational designs.
• They frame how the FDA views the asset: Protara has already disclosed that, based on discussions with the Agency, it plans to start a registrational trial comparing TARA-002 against intravesical chemotherapy in BCG-naïve patients in 2H 2026.
• They support the idea that TARA-002 can generate durable immune-mediated control of CIS in a sizeable fraction of patients, which is a critical pre-condition for any later bid at BCG-unresponsive.

BCG-unresponsive disease is obviously a tougher biology, with prior exposure to immunostimulatory treatment and often more aggressive, refractory tumours. However, the BCG-naïve data give a starting point for expectations: the market will likely look for a combination of “respectable” CR rates and any signs of duration of response in the ASCO GU dataset.

In other words, ASCO GU is not coming in a vacuum. The BCG-naïve track record, combined with the FDA feedback on a planned registrational trial, already shows that TARA-002 is more than a concept slide. The unknown is how far that performance will translate into a post-BCG setting.

3. The ASCO GU 2026 catalyst: BCG-unresponsive CIS, study design and what to watch

The upcoming ASCO GU 2026 presentation is built around the BCG-unresponsive cohort of ADVANCED-2. According to Protara’s January 22, 2026 press release, updated interim data from this cohort will be featured in a poster session at the symposium, with approximately 25 six-month evaluable patients expected in the interim dataset.

The high-level design for the BCG-unresponsive cohort can be summarised as follows (based on company disclosures and clinical trial documentation):

• Population: adults with biopsy-confirmed NMIBC, carcinoma in situ (CIS) with or without concomitant papillary disease (Ta/T1), meeting current definitions of BCG-unresponsive (adequate prior BCG exposure and persistent or recurrent disease).
• Regimen: intravesical TARA-002 given in induction and maintenance cycles, with the possibility of combining intravesical instillation with priming or maintenance subcutaneous dosing in future cohorts.
• Primary endpoints (Phase 2): complete response rate at prespecified timepoints, durability of response and safety.
• Key secondary/expansion endpoints: duration of CR, time to cystectomy, high-grade recurrence-free survival and translational biomarker work.

For investors and traders, the checklist for ASCO GU is relatively straightforward:

• CR rate in BCG-unresponsive CIS: how does the six-month CR rate compare, on an apples-to-pears basis, with published data for other intravesical or systemic agents in BCG-unresponsive NMIBC?
• Depth and durability: beyond point estimates, what proportion of responders remain disease-free at 12 months or longer, even if numbers are still small?
• Safety and tolerability: is the profile consistent with or milder than BCG and other intravesical immunotherapies, and do we see any serious immune-mediated toxicity that could limit use?
• FDA dialogue and path forward: does Protara provide any new colour on potential registration paths in BCG-unresponsive disease, or does it keep the main regulatory “ask” focused on the BCG-naïve comparator trial?

If the CR rates and safety profile look competitive, even on a modest sample size, the ASCO GU poster can act as a credibility unlock: it would confirm that the biology seen in BCG-naïve patients is not restricted to first-line disease and that TARA-002 has room to play either standalone or in combination regimens across the NMIBC spectrum.

On the other hand, a clearly weak CR rate or unexpected safety signal would push the NMIBC narrative into the background and shift the focus almost entirely onto LMs and IV Choline Chloride.

4. Pediatric lymphatic malformations: de-risking biology and a rare disease lever

TARA-002 is not purely an NMIBC bet. The LM programme gives the asset an entirely different risk/reward profile, both biologically and commercially.

In STARBORN-1, a Phase 2 trial in pediatric patients with macrocystic and mixed lymphatic malformations, Protara has reported meaningful reductions in lesion volume and improvements in symptoms after a limited number of injections. Importantly, these effects are being seen in a setting with no FDA-approved therapies specifically indicated for LMs, and where historical OK-432 experience has already shown that immune stimulation can remodel these lesions.

The FDA’s decision to grant both Breakthrough Therapy and Fast Track designations to TARA-002 in pediatric LMs confirms that regulators see this as a potentially practice-changing therapy in a rare, high-burden pediatric condition. Combined with the existing Rare Pediatric Disease designation, this opens the door to a priority review voucher if TARA-002 is eventually approved.

From an investor perspective, the LM programme does three things:

• It de-risks the mechanism: seeing immune-mediated effects outside of bladder cancer helps validate the underlying biology.
• It creates a separate regulatory path, potentially faster and less crowded than NMIBC, with the additional incentive of a pediatric voucher.
• It gives Protara a negotiating chip in any future partnering discussions: an asset with both oncology and rare disease optionality is structurally more interesting.

In its January 12, 2026 milestones update, the company stated it plans to provide a regulatory update on the registration path for TARA-002 in LMs in the first half of 2026. That update will be another important checkpoint: it can clarify whether the LM programme is moving toward a defined registrational design or remains exploratory while NMIBC takes the lead.

5. Financial position: dilution history, runway into 2028 and what it means for the catalyst

Protara’s balance sheet has changed materially over the last two years and it is crucial to separate older numbers from the current picture.

Based on the company’s SEC filings:

• As of March 31, 2024, Protara reported approximately $55M in cash and cash equivalents, plus about $3M in marketable debt securities, for a total current asset position just under $58M.
• A subsequent financing and share issuance in 2024 increased common shares outstanding and boosted paid-in capital, as reflected in the June 30, 2024 Form 10-Q.
• As of March 31, 2025, cash and cash equivalents had grown to approximately $91.5M, with a further $32.9M in current marketable debt securities and $33.2M in non-current marketable debt securities, for a total cash and securities position of about $158.6M.

The real inflection came later:

• In December 2025, Protara closed an underwritten public offering of common stock for approximately $86M gross proceeds, according to the company’s GlobeNewswire press release and the related SEC filings.
• In its January 12, 2026 milestones update, management stated that the proceeds from this offering are expected to extend the company’s cash runway into 2028.

Put together, this means:

• TARA faces the ASCO GU NMIBC readout with no immediate need to raise capital if data are at least decent.
• The company has room to fund the planned registrational trial in BCG-naïve NMIBC, continue STARBORN-1 in LMs and advance the IV Choline programme, without being forced into distressed terms.
• Any meaningful positive re-rating on data could therefore be used more strategically, for example to strengthen the balance sheet further or negotiate partnering deals from a position of relative strength.

The flip side is that existing shareholders have already absorbed substantial dilution to get here. If the NMIBC story disappoints, the equity can still be repriced sharply, even though near-term liquidity is not in question.

6. Competitive context and risk framework for NMIBC

NMIBC has become one of the most competitive territories in urologic oncology, with multiple approved or late-stage therapies targeting the BCG-unresponsive segment and a long pipeline of intravesical, systemic and gene therapy approaches. Any TARA-002 positioning has to be read against that backdrop.

This deep dive does not attempt to recreate a full competitive landscape, but a few points shape the risk framework:

• Differentiation vs existing therapies: TARA-002 offers a cell-based immunopotentiator approach with intravesical delivery and potential flexibility for combination and priming strategies. The question is whether its efficacy and safety profile can stand out enough to justify another entrant in an already busy space.
• Trial design and endpoints: regulators in NMIBC care not only about CR rate but also about durability, cystectomy-free survival and high-grade recurrence-free survival. Early ASCO GU data will not settle these questions, but they will set the tone for whether a registrational path looks realistic.
• Operational execution: Protara must execute across NMIBC, LMs and IV Choline simultaneously, each with its own regulatory pathway and operational demands.
• Small-cap volatility: even with solid cash, TARA remains a low-float, small-cap biotech. Headline risk – positive or negative – will likely translate into amplified price moves.

For traders, this is a classic “data-driven, high-volatility” setup:

• The catalyst date is clear (ASCO GU 2026, poster on February 27).
• The company has already set expectations publicly (approximately 25 six-month evaluable BCG-unresponsive patients).
• The balance sheet is solid enough that the story does not hinge on a one-day financing reaction.

The real work is in deciding whether the combination of existing BCG-naïve data, LM optionality and the BCG-unresponsive readout justifies the current valuation – and whether the risk/reward around the event fits your strategy and time horizon.

This report deliberately stops short of that decision. Its goal is narrower: to make sure that when you look at the chart, you know what is actually driving the next big move and which documents you need to read before taking a position.

7. Key primary sources (English)